When the FDA converts an accelerated approval into a full nod, it’s typically associated with a wider label for the drug at hand. But in the case of Johnson & Johnson’s Balversa, the FDA narrowed the ...
Friday afternoon, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application (sNDA) for Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial ...
Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have fibroblast growth factor receptor (FGFR) gene ...
Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said. The recent approval of Balversa (erdafitinib) ...
New York, USA, March 04, 2025 (GLOBE NEWSWIRE) -- BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight DelveInsight's "BALVERSA Market Size, Forecast, and ...
The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer. The Food and Drug Administration (FDA) approved Balversa (erdafitinib) for ...
DUBLIN--(BUSINESS WIRE)--The "Balversa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Balversa - Drug Insight, 2019 report provides comprehensive information of the ...
BEERSE, BELGIUM, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA ® (erdafitinib) ...
Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...
Johnson & Johnson JNJ announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), ...
Johnson & Johnson JNJ announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking full approval for Balversa (erdafitinib) as a treatment for patients with metastatic ...
Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results